Method for synthesizing and purifying cannabinoic acid and acylated derivatives thereof

By reacting the crude plant extract with an acylating agent and a chemical base to generate THCA alkanoate and CBDA dialkanoate, and the problem of decarboxylation of cannabinoids under high temperature conditions was solved, and high purity and stability were obtained Crystallized form, simplifying the separation process.

CN119095818APending Publication Date: 2024-12-06TRESCO HLDG GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280089751.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-11-30
Filing Date
2022-11-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

In the prior art, the isolation and purification methods of cannabinoids are complex and difficult to achieve high purity. In particular, tetrahydrocannabinol acid (THCA) and cannabidiol acid (CBDA) are prone to decarboxylation under high temperature conditions, resulting in unstable compounds and difficult to crystallize. .

Method used

By reacting the crude plant extract with an acylating agent and a chemical base, THCA alkanoate and CBDA dialkanoate are generated, and the stable pure crystalline form of the compound is obtained by crystallization, avoiding high temperature decarboxylation and chromatography separation. step.

Benefits of technology

The high-purity crystalline forms of THCA and CBDA are achieved, which improves the stability and processability of the compounds, avoids the decarboxylation problem, and simplifies the separation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095818A_ABST
    Figure CN119095818A_ABST
Patent Text Reader

Abstract

The present invention relates to a novel process for the synthesis and / or purification of tetrahydrocannabinolic acid (THCA) alkanoates and / or cannabidiol acid (CBDA) dialkanoates. The invention also provides novel derivatives of CBDA dialkanoic acid ester and THCA alkanoic acid ester with the structure as shown in the formula (I). # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to a novel method for synthesizing and / or purifying tetrahydrocannabinolic acid (THCA) alkanoate and / or cannabidiolic acid (CBDA) dialkanoate. The present invention also discloses novel derivatives of CBDA dialkanoate and THCA alkanoate. Background Art

[0002] Cannabinoids are terpene phenols found in flowering plants of the genus Cannabaceae, such as common cannabis (Cannabis sativa), Indian cannabis (Cannabis indica) and wild cannabis (Cannabis ruderalis). They are divided into 12 categories: cannabigerols (CBG), cannabichromenes (CBC), cannabiiols (CBD), dehydrocannabidiols (CBND), tetrahydrocannabinols (THC), cannabinols (CBN), cannabitriols (CBT), cannabielsoins (CBE), isocannabinoids (isocannabinoids), cannabicyclols (CBL), cannabicitrans (CBT) and cannabichromanones (CBCN).

[0003] Cannabis extracts and concentrates (oils and resins, which contain different types and amounts of cannabinoids depending on the extraction method) have been used in the medical field. Some cannabinoids, such as (-)-trans-cannabidiol (CBD) and (-)-Δ 9 -trans-THC (Δ 9 -THC, Dronabinol), exhibits different physiological effects by binding to the cannabinoid receptors CB1 and CB2 of the endocannabinoid system, and is also used as a drug to regulate appetite, pain, mood and memory (CB1) or affect the immune system (CB2). The biosynthesis of the latter cannabinoid includes the formation of cannabidiol acid (CBDA), which is then enzymatically decarboxylated to CBD or cyclized to tetrahydrocannabinol acid (THCA). During the extraction process, CBDA and THCA are decarboxylated to CBD and THC, respectively, under high temperature reaction conditions.

[0004] Methods for isolating cannabinoids are known in the art.

[0005] Formato et al. (Molecules 25, 2020, 2638) reviewed various aspects of (-)-cannabidiolic acid. CBDA is biologically active and is an anti-inflammatory, antiemetic, anticonvulsant and anticancer agent. Formato et al. described a method for extracting CBDA and THCA from the "pollen" or trichomes of industrial hemp varieties and identified analytical quantities of CBDA by distinguishing CBDA from THCA using preparative thin layer chromatography. However, a single spot on a glass plate coated with silica is not a convenient method for studying large amounts of organic compounds.

[0006] Currently, methods for synthesizing CBDA, including purifying CBDA from cannabis biomass, remain complex and do not achieve the desired purity.

[0007] Current methods for isolating and purifying cannabinoids are largely influenced by the known fact that, with the exception of CBD, pure cannabinoids are generally oily compounds that are difficult to crystallize. In addition, valuable intermediates such as THCA and CBDA obtained during the synthesis process and through bioproduction tend to decarboxylate to CBD and THC, respectively, during exposure to the high temperatures required for extraction, vacuum distillation, and even during long-term storage at room temperature.

[0008] Therefore, it is necessary to further simplify the existing process and improve the existing technology to ensure the integrity of the compound and obtain higher compound purity.

[0009] Furthermore, there is a need to derive and isolate valuable intermediate compounds and to provide novel cannabinoid derivatives that can be obtained by separation and purification techniques.

[0010] The above objectives can be achieved through the claims of the present invention and the specific technical solutions described below. Summary of the invention

[0011] In one aspect, the present invention provides a compound shown in Formula I

[0012]

[0013] Among them, R 1 is methyl-4-(prop-1-en-2-yl)-cyclohex-1-en-3-yl (limonenyl);

[0014] R 2 is acetate, propionate, butyrate or OH;

[0015] R 3 is propyl, pentyl or heptyl;

[0016] R 4 is methyl, ethyl or propyl;

[0017] R 5 is methyl, ethyl or propyl, or

[0018] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl or methyl-4-(-2-propyl)-cyclohex-5-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, and R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 is methyl, ethyl or propyl, and R 5 is methyl, ethyl or propyl,

[0019] or

[0020] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, where R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 and R 5 Does not exist, that is, R 4 and R 5 connected to a single bond and forming a ring structure.

[0021] Therefore, the present invention provides a novel synthetic route for cannabinoid acid derivatives, which are further converted into novel THC derivatives.

[0022] In another aspect, the present invention provides a method for synthesizing and / or purifying tetrahydrocannabinolic acid (THCA) alkanoate and / or cannabichromenic acid (CBDA) dialkanoate, preferably tetrahydrocannabinolic acid (THCA) acetate and / or cannabichromenic acid (CBDA) diacetate, comprising the following steps:

[0023] - Providing a crude plant extract containing a mixture of cannabinoid acids, or providing CBDA;

[0024] - contacting and / or reacting the crude plant extract or CBDA with an acylating agent, preferably an acetylating agent, and a chemical base to obtain THCA alkanoate and / or CBDA dialkanoate, preferably THCA acetate and / or CBDA diacetate; and

[0025] - separating the THCA alkanoates and / or CBDA dialkanoates obtained, preferably THCA acetate and / or CBA diacetate,

[0026] Wherein, the acylating agent is selected from C 1 -C 10 an aliphatic or aromatic anhydride, preferably acetic anhydride,

[0027] Wherein, the chemical base is preferably a tertiary amine, such as pyridine or preferably triethylamine,

[0028] Among them, separation is carried out by crystallization.

[0029] This chemical method for isolating CBDA from crude plant extracts by preparing derivatives of CBDA and THCA is simple, effective, and also allows the separation of CBDA from a different mixture of chemical carboxylation products of CBD.

[0030] The method according to the present invention separates the target compound by simple crystallization of the chemically modified derivative, thus avoiding the time-consuming and laborious chromatographic separation of cannabinoids.

[0031] The method provided by the present invention is very advantageous because it provides pure crystalline forms of THCA acetate and CBDA diacetate, as opposed to other oily cannabinoids that are difficult to crystallize. In addition, the method avoids and / or solves the problem that THCA is unstable and very susceptible to decarboxylation. In particular, THCA acetate cannot be decarboxylated and is much more stable than THCA.

[0032] In another aspect, the present invention provides a compound of formula I for use in medicine.

[0033] Cannabinoid derivatives have shown a wide range of health benefits and applications in the medical field, and can be used to treat inflammation, nausea, seizures and even cancer in humans and / or animals. DETAILED DESCRIPTION

[0034] Novel CBDA and THCA derivatives

[0035] In one aspect, the present invention provides a compound shown in Formula I

[0036]

[0037]

[0038] Among them, R 1 is methyl-4-(prop-1-en-2-yl)-cyclohex-1-en-3-yl (limonenyl);

[0039] R 2 is acetate, propionate, butyrate or OH;

[0040] R 3 is propyl, pentyl or heptyl;

[0041] R 4is methyl, ethyl or propyl;

[0042] R 5 is methyl, ethyl or propyl, or

[0043] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl or methyl-4-(-2-propyl)-cyclohex-5-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, and R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 is methyl, ethyl or propyl, and R 5 is methyl, ethyl or propyl,

[0044] or

[0045] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, where R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 and R 5 Does not exist, that is, R 4 and R 5 connected to a single bond and forming a ring structure.

[0046] Therefore, the present invention provides a novel synthetic route for cannabinoid acid derivatives, which are further converted into novel THC derivatives.

[0047] The practicality of the compounds provided by the present invention is due to the fact that they are all crystalline and their decarboxylation is hindered by the esterification of the phenolic alcohol adjacent to the carboxylic acid moiety and the esterification of the carboxylic acid itself, which increases their processability and stability. In contrast, natural products with acid functional groups are unstable and decompose at temperatures above 50°C. The above characteristics are very suitable for the extraction, purification and / or separation of cannabinoids.

[0048] In one embodiment, the present invention provides a compound shown in formula I

[0049]

[0050] Among them, R 1 is methyl-4-(prop-1-en-2-yl)-cyclohex-1-en-3-yl (limonenyl);

[0051] R2 is acetate or OH;

[0052] R 3 is propyl, pentyl or heptyl;

[0053] R 4 is methyl;

[0054] R 5 is methyl, or

[0055] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl or methyl-4-(-2-propyl)-cyclohex-5-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, and R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 is methyl, and R 5 Methyl,

[0056] or

[0057] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, where R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 and R 5 Does not exist, that is, R 4 and R 5 connected to a single bond and forming a ring structure.

[0058] The compounds provided are crystalline, thereby enabling purification and isolation from crude plant extracts, such as CBDA-diacetate and further homologues of Formula I. These compounds are value-added intermediates that facilitate particularly high yield cyclization and increase product purity to produce further derivatives, such as THCA, Tetrahydrocannabivarinic acid (THCVA), Δ 9 -Tetrahydrocannabiphorolic acid (THCPA), THC, Tetrahydrocannabivarin (THCV) and Tetrahydrocannabiphorol (THCP).

[0059] In one embodiment, there is provided a compound of formula II

[0060]

[0061] In one embodiment, there is provided a compound of formula III

[0062]

[0063] The compound of formula III is valuable and can be further derivatized to form a THCA derivative, namely the compound of formula IVa.

[0064] In one embodiment, there is provided a compound of formula IVa

[0065]

[0066] In one embodiment, there is provided a compound of formula IVb

[0067]

[0068] In one embodiment, there is provided a compound of formula V

[0069]

[0070] The compound shown in formula V is very valuable. It is a non-psychoactive derivative that can be further hydrolyzed into THCA and CO 2 , whose hydrolysis can be achieved by exposure to water or atmospheric moisture.

[0071] Pharmaceutical composition

[0072] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula I in a pharmaceutically acceptable carrier.

[0073]

[0074]

[0075] Among them, R 1 is methyl-4-(prop-1-en-2-yl)-cyclohex-1-en-3-yl (limonenyl);

[0076] R 2 is acetate, propionate, butyrate or OH;

[0077] R 3 is propyl, pentyl or heptyl;

[0078] R 4 is methyl, ethyl or propyl;

[0079] R 5 is methyl, ethyl or propyl, or

[0080] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl or methyl-4-(-2-propyl)-cyclohex-5-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, and R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 is methyl, ethyl or propyl, and R 5 is methyl, ethyl or propyl,

[0081] or

[0082] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, where R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 and R 5 Does not exist, that is, R 4 and R 5 connected to a single bond and forming a ring structure.

[0083] In one embodiment, a pharmaceutical composition is provided, comprising a compound selected from the following in a pharmaceutically acceptable carrier.

[0084]

[0085]

[0086] method

[0087] In another aspect, the present invention provides a method for synthesizing and / or purifying tetrahydrocannabinolic acid (THCA) alkanoates and / or cannabichromenic acid (CBDA) dialkanoates, preferably tetrahydrocannabinolic acid acetate and / or cannabichromenic acid diacetate, comprising the following steps:

[0088] - Providing a crude plant extract containing a mixture of cannabinoid acids, or providing CBDA;

[0089] - contacting and / or reacting the crude plant extract or CBDA with an acylating agent, preferably an acetylating agent, and a chemical base to obtain THCA alkanoate and / or CBDA dialkanoate, preferably THCA acetate and / or CBDA diacetate; and

[0090] - separating the THCA alkanoates and / or CBDA dialkanoates obtained, preferably THCA acetate and / or CBA diacetate,

[0091] Wherein, the acylating agent is selected from C 1 -C 10 an aliphatic or aromatic anhydride, preferably acetic anhydride,

[0092] Wherein, the chemical base is preferably a tertiary amine, such as pyridine or preferably triethylamine,

[0093] Among them, separation is carried out by crystallization.

[0094] This chemical process for the synthesis and / or purification of tetrahydrocannabinolic acid (THCA) alkanoates and / or cannabidiolic acid (CBDA) dialkanoates allows the separation of THCA and / or CBDA from crude plant extracts by preparing derivatives of CBDA and / or THCA. This process of the invention is simple, effective, and also allows the separation of THCA and / or CBDA from different mixtures of chemical carboxylation products of CBD.

[0095] The method of the present invention separates the target compound by simple crystallization of the chemically modified derivative, avoiding the time-consuming and laborious chromatographic separation of cannabinoids.

[0096] The method provided by the present invention is very advantageous because it provides pure crystalline forms of THCA alkanoates and / or CBDA dialkanoates, particularly THCA acetate and CBDA diacetate, as distinct from other oily cannabinoids that are difficult to crystallize. The alkanoate forms of these acids prevent decarboxylation and provide greater thermal stability for their handling and storage. The method avoids and / or solves the problem that THCA is unstable and very susceptible to decarboxylation. In particular, THCA acetate cannot be decarboxylated and is much more stable than THCA.

[0097] The steps of "contacting and / or reacting" the crude plant extract or "reacting" or "treating" any other starting compound (including any intermediate compound) with a chemical reagent or multiple chemical reagents (optionally, in a suitable solvent) mentioned in the present invention should be understood as that each step or series of steps is carried out for a time sufficient to allow (i.e., allow) at least a portion of the starting compound to react and be converted into the target compound (or intermediate). Preferably, the time is sufficient for the basic reaction to occur and to achieve chemical equilibrium between the starting compound and the target compound (or intermediate) under the respectively selected reaction or treatment conditions. Similarly, those skilled in the art understand and know how to perform the addition of chemical reagents, such as stirring and / or maintaining a preferred temperature, to optimize and / or maximize the yield of the target compound. In addition, those skilled in the art understand and know how to perform post-treatment of the reaction batch, such as adding water and / or combining with HCl aqueous solution for neutralization purposes, using an organic solvent for extraction, washing with, for example, HCl aqueous solution or saturated NaCl solution, washing with Na 2 SO 4 Dry, filter and concentrate to optimize and / or maximize the yield of the target compound.

[0098] In one embodiment, the crude plant extract is provided by enzymatic hydrolysis. Advantageously, the method does not generate so much heat during the enzymatic extraction process that materials sensitive to decarboxylation are not decarboxylated.

[0099] In one embodiment, a crude plant extract containing a mixture of cannabinoid acids is provided, comprising providing cannabis pollen, preferably isolating trichomes from plant inflorescences by an optional sieving process, and subjecting the cannabis pollen to an enzymatic hydrolysis process, wherein the cellulose of the plant cell wall is hydrolyzed and / or enzymatically decomposed at a temperature between 10° C. and 40° C., preferably between 20° C. and 30° C. to release cannabinoids into an aqueous solution. The enzymatic process is advantageous in keeping CBDA in the acid form and preventing it from being decarboxylated.

[0100] In one embodiment, a crude plant extract containing a mixture of cannabinoid acids is provided, comprising providing cannabis pollen, preferably separating trichomes from plant inflorescences by an optional sieving process. The cannabis pollen is subjected to ultrasonic accelerated maceration using alternating pressure and cavitation to achieve at least partial cell decomposition and / or at least partial release of intracellular metabolic contents, and the cannabinoid acids are extracted by using a solvent, preferably a chloroform / n-hexane (1:1, v / v) solvent mixture, at a temperature between 10°C-40°C, preferably 20°C-30°C. This cold extraction method is advantageous in keeping CBDA in the acid form and preventing its decarboxylation.

[0101] In one embodiment, the step of extracting cannabinoid acids using a solvent, preferably a chloroform / n-hexane (1:1, v / v) mixture, is performed batch by batch, using 10g-50g of cannabis pollen (HP) per batch, the ratio of HP to solvent (or solvent mixture) is 1:4-1:6 (w / w), and the extraction is repeated three times. Preferably, each extraction lasts at least 10 minutes, more preferably at least 30 minutes.

[0102] In one embodiment, the crude plant extract is contacted and / or reacted with an acylating agent (preferably an acetylating agent) and a chemical base, wherein the acylating agent is selected from C 1 -C 10 Aliphatic or aromatic anhydride, preferably acetic anhydride, and wherein the chemical base is preferably a tertiary amine, such as pyridine or preferably triethylamine, comprising dissolving the plant crude extract in a suitable solvent (such as DMF) under shaking at room temperature, adding the acylating agent dropwise under stirring and keeping the solvent temperature below 50°C, and further contacting and / or reacting at room temperature for 1-4 hours, preferably 1.5-2.5 hours. The method steps provide a synthetic method for obtaining THCA alkanoate and / or CBDA dialkanoate, preferably THCA acetate and / or CBADA diacetate.

[0103] The room temperature mentioned in the present invention should be understood as a temperature range between 18-30°C, preferably between 21-24°C.

[0104] In one embodiment, the acylating agent is selected from C 1 -C 10 Aliphatic or aromatic anhydrides, for example propionic anhydride, butyric anhydride, valeric anhydride, caproic anhydride, heptanoic anhydride, octanoic anhydride, nonanoic anhydride, decanoic anhydride, benzoic anhydride and substituted benzoic anhydrides, preferably acetic anhydride.

[0105] In one embodiment, the chemical base is a tertiary amine, such as pyridine, diisopropylethylamine or preferably triethylamine. Triethylamine is relatively cheap and easy to remove from the reaction mixture, which is more advantageous than many chemical bases (such as pyridine) that can be used in the process.

[0106] In one embodiment of the method, after the step of contacting and / or reacting the plant crude extract with the acylating agent and the chemical base, the following steps are further included: cooling to 0° C., adding water to the contacted and / or reacted plant crude extract (e.g., reaction mixture), stirring at room temperature for 0.5 h, combining with an aqueous HCl solution (about 2 M), extracting with ethyl acetate twice, washing the combined ethyl acetate extracts (about 2 M) with an aqueous HCl solution, and then washing with a saturated NaCl solution three times, Na 2 SO 4 Dry, filter and concentrate.

[0107] In one embodiment of the method, the obtained THCA alkanoate and / or CBDA dialkanoate, preferably THCA acetate and / or CBAD diacetate, is separated by crystallization. Those skilled in the art know and understand that crystallization includes complete dissolution of the crude product or raw material in the solvent, preferably by heating the solvent to achieve and / or accelerate dissolution, but setting and / or maintaining a temperature below the decomposition temperature of the crude product or raw material, optionally filtered through a layer of silica gel, followed by cooling to obtain crystals of the product or raw material.

[0108] THCA alkanoates and / or CBDA dialkanoates, preferably THCA acetate and / or CBADA diacetate, are conducive to crystallization, while most other cannabinoid compounds and derivatives are oily, difficult to handle and difficult to process. In particular, crystallization of THCA alkanoates and / or CBDA dialkanoates, preferably THCA acetate and / or CBA diacetate is feasible and simple.

[0109] For CBDA and THCA, the free, underivatized acid cannot be crystallized because heating would cause decarboxylation. Advantageously, THCA alkanoates and / or CBDA dialkanoates, preferably THCA acetate and / or CBA diacetate, can be crystallized without decarboxylation, thereby leaving the chemical derivatives intact.

[0110] In one embodiment of the method, the crystallization is carried out in n-pentane or n-hexane. Advantageously, n-pentane or n-hexane, in particular the low boiling point of n-pentane, can provide suitable crystallization conditions for the derivative compound, i.e., THCA alkanoate and / or CBDA dialkanoate, preferably THCA acetate and / or CBA diacetate, so that its structure can remain intact, and thus advantageously prevent decay reactions, such as decarboxylation reactions.

[0111] In one embodiment, a method for synthesizing and / or purifying THCA alkanoate, preferably THCA acetate, is provided, comprising the steps of:

[0112] -Providing crude plant extracts containing a mixture of cannabinoid acids;

[0113] - contacting and / or reacting the crude plant extract with an acylating agent (preferably an acetylating agent) and a chemical base to obtain a THCA alkanoate, preferably THCA acetate; and

[0114] - separating the THCA alkanoate obtained, preferably THCA acetate,

[0115] Wherein, the acylating agent is selected from C 1 -C 10 an aliphatic or aromatic anhydride, preferably acetic anhydride,

[0116] Wherein, the chemical base is preferably a tertiary amine,

[0117] Among them, separation is carried out by crystallization.

[0118] In one embodiment, a method for synthesizing and / or purifying cannabidiol acid (CBDA) dialkanoate, preferably cannabidiol acid (CBDA) diacetate, is provided, the method comprising the following steps:

[0119] - Provide CBDA;

[0120] - contacting and / or reacting CBDA with an acylating agent, preferably an acetylating agent, and a chemical base to obtain a CBDA dialkanoate, preferably CBDA diacetate; and

[0121] - separating the obtained CBDA dialkanoate and CBDA diacetate,

[0122] Wherein, the acylating agent is selected from C 1 -C 10 an aliphatic or aromatic anhydride, preferably acetic anhydride,

[0123] Wherein, the chemical base is preferably a tertiary amine,

[0124] Among them, separation is carried out by crystallization.

[0125] In one embodiment, the step of treating the obtained CBDA diacetate with an alkylating agent to obtain a first CBDA diacetate derivative, preferably CBDA diacetate methyl ester of formula II, wherein the alkylating agent can be, for example, C 1 -C 10 dialkyl sulfate, preferably dimethyl sulfate,

[0126]

[0127] In one embodiment, the step of treating the obtained CBDA diacetate with an alkylating agent comprises dissolving the CBDA diacetate in a solvent, preferably acetonitrile, and adding an excess of triethylamine, preferably 1.1 molar equivalents of triethylamine relative to the CBDA diacetate, while stirring the solution at room temperature, and adding an excess of dimethyl sulfate dropwise to the stirred solution, preferably 1.1 molar equivalents relative to the CBDA diacetate. The temperature is maintained at or below 50° C., and the solution is further stirred at room temperature.

[0128] In an optional embodiment, the step of treating the obtained CBDA diacetate with an alkylating agent comprises dissolving CBDA diacetate in a solvent, preferably acetonitrile, and adding an excess of triethylamine, preferably 1.1 molar equivalents of triethylamine relative to CBDA diacetate, while stirring the solution at room temperature, and adding an excess of dimethyl sulfate dropwise to the stirred solution, preferably 1.1 molar equivalents relative to CBDA diacetate. The temperature is maintained at about 60° C. for 2 hours, and the reaction solution is poured into an ice-cold 1M HCl aqueous solution, and the resulting suspension is extracted twice with dichloromethane, and the combined organic extracts are treated with 1M HCl aqueous solution, saturated NaHCO 3 aqueous solution and saturated NaCl aqueous solution, Na 2 SO 4 dry.

[0129] In one embodiment, the method further comprises the step of removing the acyl group of the first CBDA diacetate derivative to obtain a CBDA monoacetate derivative, preferably CBDA-2-acetate methyl ester of formula III

[0130]

[0131] In one embodiment, the step of removing the acyl group of the first diacetate derivative comprises dissolving the first CBDA-diacetate derivative in an alcohol (e.g., methanol), adding an alkaline reagent (e.g., a methanol solution of sodium methoxide or ammonia), and stirring at room temperature for 24 hours. In one embodiment in which sodium methoxide is added, the method further comprises the steps of neutralizing the solution by adding AmberlystIR 120 ion exchange resin (its protonated form), filtering, and concentrating. In one embodiment in which ammonia is added, the method further comprises the step of concentrating the solution.

[0132] In one embodiment, the method further comprises the step of converting the CBDA monoacetate derivative into a THCA monoacetate derivative, preferably THCA 2-acetate methyl ester of formula IVa.

[0133]

[0134]

[0135] In one embodiment, the step of converting the CBDA monoacetate derivative into the THCA monoacetate derivative comprises dissolving the CBDA monoacetate derivative in dichloromethane and adding boron trifluoride etherate, stirring under a protective gas atmosphere, preferably nitrogen, with saturated NaHCO 3 aqueous solution, 2N HCl aqueous solution, saturated NaCl aqueous solution, Na 2 SO 4Dry and filter. In another embodiment, the method further comprises the steps of concentrating the filtrate and recrystallizing from n-hexane.

[0136] In one embodiment, the step of converting the CBDA monoacetic acid derivative into the THCA monoacetic acid derivative comprises dissolving the CBDA monoacetic acid derivative in dichloromethane, adding boron trifluoride etherate together with a mixture of trialkylamine (preferably diisopropylethylamine) and tetraethylene glycol dimethyl ether, stirring under a protective gas atmosphere, and heating with saturated NaHCO 3 aqueous solution, 2N HCl aqueous solution, saturated NaCl aqueous solution, Na 2 SO 4 Dry and filter. In another embodiment, the method further comprises the steps of concentrating the filtrate and recrystallizing from n-hexane.

[0137] In one embodiment, a method is disclosed, comprising the steps of converting CBD monoacetate into THC monoacetate, the method comprising dissolving CBD monoacetate in dichloromethane, adding boron trifluoride etherate together with a mixture of trialkylamine (preferably diisopropylethylamine) and tetraethylene glycol dimethyl ether, stirring under a protective gas atmosphere, and heating with saturated NaHCO 3 aqueous solution, 2N HCl aqueous solution, saturated NaCl aqueous solution, Na 2 SO 4 Dry and filter. In another embodiment, the method further comprises the steps of concentrating the filtrate and recrystallizing from n-hexane.

[0138] The use of a mixture of trialkylamine (preferably diisopropylethylamine) and tetraethylene glycol dimethyl ether can adjust the activity of boron trifluoride diethyl ether, thereby enabling kinetic control to produce Δ 9 -THC ratio produces Δ 8 -THC dominates. Thus, this approach creates an environment by which Lewis acid-catalyzed cyclization of CBD (or CBDA) leads to kinetically controlled Δ 9 -THC (or Δ 9 -THCA) synthesis.

[0139] In contrast, under thermodynamic control, the protonation of the cyclohexene double bond in CBD or CBDA promotes the formation of a tertiary carbon ion, which results in Δ 8 -THC production reaches Δ 8 -THc and Δ 9 -THC, the thermodynamic equilibrium exists between them, with a ratio of 97 / 3.

[0140] In one embodiment, the volume / volume ratio of the mixture of trialkylamine, preferably diisopropylethylamine, and tetraethylene glycol dimethyl ether includes diisopropylethylamine / tetraethylene glycol methyl ether 30 / 70-70 / 30, preferably a volume / volume ratio of diisopropylethylamine / tetraethylene glycol dimethyl ether of 40 / 60-60 / 40, more preferably a volume / volume ratio of diisopropylethylamine / diethylene glycol diethyl ether of 45 / 55 to 55 / 45, and most preferably a volume / volume ratio of diisopropylamine / tetraethylene glycol dimethyl ether of 50 / 50.

[0141] In one embodiment, the method further comprises the step of converting the THCA 2-acetate methyl ester into the THCA carbonate of formula V, preferably via a THCA intermediate

[0142]

[0143] In one embodiment, the step of converting THCA 2-acetate methyl ester comprises dissolving THCA 2-acetate in an alcohol solution of 0.5-2.0 M LiOH, preferably methanol, preferably about 1 M LiOH, and stirring the solution for 12-36 hours, preferably about 24 hours. In another embodiment, the method further comprises the step of reacting with an aqueous solution of HCl (preferably at a concentration of 2 M), extracting twice with dichloromethane, washing the combined extracts with a saturated aqueous solution of NaCl, and rinsing the resulting mixture with a saturated aqueous solution of NaCl. 2 SO 4 Dry, filter and concentrate to obtain crude THCA.

[0144] In another embodiment, the method further comprises the steps of: dissolving crude THCA in an aromatic solvent such as toluene, adding an alkaline reagent such as trimethylamine and phosgene, preferably 2M phosgene, stirring at room temperature, and saturated NaHCO 3 Aqueous solution washing, Na 2 SO 4 Dry, filter and concentrate to obtain THCA carbonate.

[0145] In one embodiment of the method, the purity of the obtained derivative is at least 70%, preferably 90%, more preferably 99%, wherein the obtained derivative is selected from

[0146]

[0147]

[0148] In one embodiment of the method, there is no distillation step and / or no chromatography (chromatographic separation) step. Advantageously, cumbersome and expensive chromatography steps are avoided. Advantageously, a distillation step is avoided because the compounds are thermolabile and may decompose at temperatures above room temperature, preferably 20° C. above room temperature. In particular, the absence of a distillation step prevents decarboxylation of THCA alkanoates and / or CBDA-dialkanoates, preferably THCA acetate and / or CBDA-diacetate, during or as part of the process.

[0149] In one embodiment of the method, the plant extract is obtained from a plant of the Cannabinaceae family, preferably selected from the group consisting of Cannabis sativa, Cannabis indica and Cannabis ruderalis. The plant extract obtained from said plant is naturally rich in cannabinoids and is therefore useful for the synthesis and / or purification of THCA alkanoates and / or CBDA-dialkanoates, preferably THCA acetate and / or CBA-diacetate.

[0150] In another aspect, the present invention provides a method for converting CBD into Δ 9 -THC method, comprising the steps of:

[0151] - preparing a first solution comprising CBD in an organic solvent;

[0152] - preparing a second solution comprising tetraethylene glycol dimethyl ether, diisopropylethylamine and boron trifluoride diethyl ether complex dissolved in an organic solvent;

[0153] - adding the first solution to the second solution to obtain a reaction mixture;

[0154] - optionally adding a further portion of the second solution to the reaction mixture; and

[0155] - Get Δ 9 -THC,

[0156] Wherein, the conversion of CBD into Δ 9 -THC is carried out at a temperature of 10°C to 40°C, preferably 20°C to 30°C, the conversion of CBD into Δ 9 -THC was carried out under a protective gas atmosphere.

[0157] In one embodiment, the protective gas atmosphere is a nitrogen atmosphere. In an optional embodiment, the protective gas atmosphere is an argon atmosphere.

[0158] In one embodiment, the present invention provides a method for converting CBD into Δ 9 -THC method, comprising the steps of:

[0159] - preparing a first solution comprising CBD in an organic solvent;

[0160] - preparing a second solution comprising tetraethylene glycol dimethyl ether, diisopropylethylamine and boron trifluoride diethyl ether complex dissolved in an organic solvent;

[0161] - adding the first solution to the second solution to obtain a reaction mixture;

[0162] - optionally adding a further portion of the second solution to the reaction mixture; and

[0163] - Get Δ 9 -THC,

[0164] Wherein, the conversion of CBD into Δ 9 -THC is carried out at a temperature of 10°C to 40°C, preferably 20°C to 30°C, the conversion of CBD into Δ 9 -THC was carried out under a protective gas atmosphere.

[0165] In one embodiment, CBD is converted to Δ 9 -THC method further comprising the steps of:

[0166] - washing the reaction mixture with a neutralizing solution, for example aqueous HCl;

[0167] - repeatedly washing the reaction mixture with NaCl solution; and

[0168] - Drying the reaction mixture, e.g. Na 2 SO 4 The reaction mixture is dried, optionally filtered, and the organic solvent evaporated.

[0169] In another aspect, the present invention provides a method for synthesizing cannabidiol acid (CBDA), comprising the steps of:

[0170] - preparing a solution comprising CBD in an organic solvent;

[0171] - adding a non-nucleophilic base to the solution, wherein the non-nucleophilic base is preferably DBU (1,8-diazabicyclo[5.4.0]undec-7-ene); and

[0172] - introducing carbon dioxide into the solution, preferably by bubbling carbon dioxide into the solution, to obtain CBDA.

[0173] This method provides CBDA in high purity and high yield.

[0174] In one embodiment, the present invention provides a method for synthesizing cannabidiol acid (CBDA), comprising the steps of:

[0175] - providing a solution comprising CBD in an organic solvent (e.g., acetonitrile and DMF);

[0176] - adding a non-nucleophilic base to the solution, wherein the non-nucleophilic base is preferably DBU (1,8-diazabicyclo[5.4.0]undec-7-ene); and

[0177] - introducing carbon dioxide into the solution, preferably by bubbling carbon dioxide into the solution, to obtain CBDA;

[0178] - washing the solution with a neutralizing solution, for example aqueous hydrogen chloride solution;

[0179] - optionally, repeatedly washing the solution with NaCl solution; and

[0180] - extracting said solution with a second organic solvent to obtain an extract, optionally drying said extract, and evaporating said second organic solution from said extract to obtain CBDA, preferably in crystalline form.

[0181] Drug Application

[0182] Another aspect of the present invention provides a compound of formula I for use in medicine,

[0183] Among them, R 1 is methyl-4-(prop-1-en-2-yl)-cyclohex-1-en-3-yl (limonenyl);

[0184] R 2 is acetate, propionate, butyrate or OH;

[0185] R 3 is propyl, pentyl or heptyl;

[0186] R 4 is methyl, ethyl or propyl;

[0187] R 5 is methyl, ethyl or propyl, or

[0188] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl or methyl-4-(-2-propyl)-cyclohex-5-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, and R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R4 is methyl, ethyl or propyl, and R 5 is methyl, ethyl or propyl,

[0189] or

[0190] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, where R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 and R 5 Does not exist, that is, R 4 and R 5 connected to a single bond and forming a ring structure.

[0191] Another aspect of the present invention provides a compound of formula II for use in medicine.

[0192] Another aspect of the present invention provides a compound of formula III for use in medicine.

[0193] Another aspect of the present invention provides a compound of formula IVa for use in medicine.

[0194] Another aspect of the present invention provides a compound of formula IVb for use in medicine.

[0195] Another aspect of the present invention provides a compound of formula V for use in medicine.

[0196] Cannabinoid derivatives have shown a wide range of health benefits and applications in medicine, including the treatment of inflammation, nausea, seizures, and even cancer in humans and / or animals.

[0197] In one embodiment, a compound of formula I is provided for treating or preventing a disease associated with cannabinoid receptors, wherein the cannabinoid receptors are one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR19, TRPV1, TPRV2, PPARy or μ-opioid receptors.

[0198] In one embodiment, a compound of Formula II, Formula III, Formula IVa, Formula IVb or Formula V is provided for treating or preventing a disease associated with a cannabinoid receptor, wherein the cannabinoid receptor is one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR19, TRPV1, TPRV2, PPARy or μ-opioid receptor.

[0199] In one embodiment, the compound of formula I is provided for use in treating or preventing a disease associated with cannabinoid receptors, wherein the cannabinoid receptors are CB1 and / or CB2.

[0200] In one embodiment, a compound of Formula II, Formula III, Formula IVa, Formula IVb or Formula V is provided for use in treating or preventing a disease associated with a cannabinoid receptor, wherein the cannabinoid receptor is CB1 and / or CB2.

[0201] Cannabinoids and their derivatives are compounds that are active at human and animal cannabinoid receptors and have been associated with pharmacological benefits for many potential disease treatments, such as chronic pain, epilepsy, sleep disorders, anxiety, cancer, glaucoma, nausea, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Crohn's disease, post-traumatic stress disorder (PTSD), arthritis, and fibromyalgia.

[0202] CB1 and CB2 receptors, as well as other receptors, are involved in regulating the activity of cannabinoids in humans and / or animals. Serotonin receptors, such as 5HT1A and 5HT2A, are known targets of cannabinoids.

[0203] Both classes of receptors, CB1 / CB2 receptors and serotonin receptors, have been implicated in several neurological phenomena, such as anxiety, appetite, cognition, and mood. Other receptors, such as GPR18, GPR55, GPR119, TRPV1, TPRV2, PPARs, and μ-μ-opioid receptors, are modulated and / or influenced, at least in part, by cannabinoids or cannabinoid-derived compounds.

[0204] In one embodiment, the present invention provides a compound of formula I for use in treating a condition associated with or benefiting from COX-2 inhibition.

[0205] Among them, R 1 is methyl-4-(prop-1-en-2-yl)-cyclohex-1-en-3-yl (limonenyl);

[0206] R 2 is acetate, propionate, butyrate or OH;

[0207] R 3 is propyl, pentyl or heptyl;

[0208] R 4 is methyl, ethyl or propyl;

[0209] R 5 is methyl, ethyl or propyl, or

[0210] Among them, R 1is methyl-4-(2-propyl)-cyclohex-1-en-3-yl or methyl-4-(-2-propyl)-cyclohex-5-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, and R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 is methyl, ethyl or propyl, and R 5 is methyl, ethyl or propyl,

[0211] or

[0212] Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, where R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 and R 5 Does not exist, that is, R 4 and R 5 connected to a single bond and forming a ring structure.

[0213] In one embodiment, the invention provides CBDA-2-acetate for use in treating a condition associated with or benefiting from COX-2 inhibition.

[0214] COX-2 inhibition can combat inflammation and inflammatory processes.

[0215] Example

[0216] Extraction of crude plant extracts

[0217] Crude plant extracts were prepared by either an enzymatic polysaccharide hydrolysis method (Herbolia) or a "cold" extraction method, both of which protect CBDA from decarboxylation.

[0218] Method 1

[0219] Dried cannabis (25 g) was ground in a mortar and suspended in n-hexane (1 L). The mixture was stirred at room temperature for 3 hours and sonicated for 15 minutes. The mixture was filtered through filter paper and the filtrate was concentrated to about 200 mL in a rotary evaporator (bath temperature 30°C) under vacuum. The light red solution was extracted with 1% aqueous NaOH (150 mL) and the alkaline aqueous extract was poured into an ice-cold 10% HCl solution (200 mL). The resulting mixture was extracted with ethyl acetate (2 x 50 mL), and the organic extract was washed with saturated NaCl solution, Na 2 SO 4Dry, filter and concentrate.

[0220] Method 2

[0221] Cannabis pollen (HP) is a resin produced from trichomes separated from plant inflorescences by sieving, which can be used to extract CBDA. Cannabis pollen obtained from a farmer at a cannabis farm laboratory (Caserta, Italy) was subjected to ultrasonic accelerated maceration (Branson UltrasonicTM M3800-E, Danbury, CT, USA), using alternating pressure and cavitation to promote cell decomposition and release of cell contents. A mixed solvent of chloroform / n-hexane (1:1, v / v) was used as the extraction liquid, and about 10 g of HP was used in each batch, with a ratio of HP to the mixed solvent of 1:5, and three extractions were performed. Each extraction lasted 30 minutes. The obtained compound mixture was rich in cannabinoids with a yield of at least 25%.

[0222] Method 3

[0223] 150g of dried industrial hemp buds were placed in a Kitchen Aid blender set at 100 rpm with a mixture of 340g of water, 100g of olive oil, 6g of citric acid monohydrate and commercial food-grade enzymes, which consisted of Celluclast 1.5L (cellulase), Ultraflow Max (β-glucanase), Pecleve (pectinase, β-glucanase, cellulase and β-mannanase) and Ceremix 2XL (α-amylase, β-glucanase, protease). The total enzyme concentration was 3% of the weight of the hemp plant material. After 3.5 hours, the mixture became homogeneous. Subsequently, the mixture was centrifuged (11000rpm, 5 minutes) to obtain 91g of fat-soluble extract, 80g of intermediate aqueous phase and 410g of wet solid components.

[0224] The lipid-soluble extract was washed with 0.1 N aqueous NaOH solution, the lipid phase was discarded, and the aqueous phase was neutralized with 2 N aqueous HCl solution, after which the crude CBDA precipitate was filtered out and centrifuged to provide crude CBDA containing oil with a purity of about 70%.

[0225] Compound synthesis and characterization

[0226] All reactions were carried out under nitrogen atmosphere and solvents were dried by standard procedures. The progress of the reaction was monitored by TLC using Polygram SIL G / UV254 silica gel plates from Macherey & Nagel and 60RP-18F254 silica gel plates from Supelco. Spots were detected by developing with sulfuric acid (5% ethanol solution), spraying the plates with an alkaline aqueous solution of potassium permanganate, developing the plates in an iodine chamber or observing the TLC plates under ultraviolet light (254 nm).

[0227] Preparative chromatography was carried out using silica gel from Macherey & Nagel (0.032-0.063 mm).

[0228] NMR spectra were recorded on the following spectrometers: Bruker Avance III HD 400 (1H: 400.2 MHz; 13C: 100.6 MHz), Bruker Avaence III HDX 600 (1H: 600.2 MHz, 13C: 150.9 MHz), and Bruker Avaence III HDX 700 (1H: 700.3 MHz; 13C: 176.1 MHz); and calibrated for the solvent signal ( 1 H:CDCl 3 :δ=7.26ppm; acetone-d 6 :δ=2.05ppm; dichloromethane-d 2 :δ=5.32ppm;DMSO-d 6 :δ=2.50ppm; 13 C:CDCl 3 :δ=77.16ppm; acetone-d 6 :δ-292ppm; dichloromethane-d 2 :δ=54.0ppm;DMSO-d 6 :δ=39.51ppm).

[0229] ESI-TOF-HRM spectroscopy was performed on a Bruker MAXIS 4G spectrometer.

[0230] Elemental analysis was performed using a HEKAtech Euro EA 3000 instrument.

[0231] The optical rotation was measured using a 10 cm cuvette of a Perkin-Elmer polarimeter 341 at 20°C and a wavelength of 589 nm (Na lamp).

[0232] Melting points were measured using a Büchi melting point apparatus M-560.

[0233] Example 1a: Isolation of CBDA-diacetate from cannabis extract

[0234]

[0235] 5 g of cannabis extract (Herbolea) containing about 70% CBDA (w / w) was dissolved in a mixed solvent of DMF (10 mL) and triethylamine (10 mL) at room temperature under shaking to obtain a dark red solution. Acetic anhydride (10 mL) was added dropwise to the stirred solution so that the temperature did not exceed 50°C. Stir at room temperature for 2 hours and cool to 0°C. 10 mL of water was added and stirred at room temperature for 0.5 hours. The mixture was poured into an aqueous HCl solution (2M, 50 mL) and extracted with ethyl acetate (2x 35 mL). The combined ethyl acetate extracts were washed with an aqueous HCl solution (2M, 1x 50 mL), then with a saturated NaCl solution (3x 50 mL), Na 2 SO 4 Dry, filter and concentrate. The brown oily residue (5.47 g) was dissolved in n-hexane / ether or alternatively in n-heptane / tert-butyl methyl ether (1 / 1 v / v, 50 mL) and filtered through a silica gel layer. The filtrate was concentrated and boiled with n-hexane (30 mL). After stopping the heating, crystallization occurred immediately to obtain white needle-shaped CBDA-diacetate (4.01 g, 93%).

[0236] The melting point of CBDA-diacetate was determined to be 127° C. (literature value: 126-128° C., R. Mechoulam, Z. Ben-Zvi, Chem. Commun. 1969 343-344).

[0237] The compound was confirmed by high resolution mass spectrometry (HRMS): theoretical value C 26 H 33 O 5 [M+Na] + m / z = 465.22476; experimental result: m / z = 465.22486. The compound was confirmed by elemental analysis: calculated C 26 H 33 O 5 :C70.56, H7.74; Experimental results: C 70.55, H 7.62.

[0238] The measured optical rotation is =-68°(c=10mg / mL; CHCl 3 ).

[0239] 1 H-NMR spectral data and 13 C-NMR spectrum data are as follows: 1 H-NMR (CDCl 3): δ=0.80(t,3H,J=6.6Hz,H-5”),1.24,1.25(2d,4H,H-3”,4”),1.52(s,3H,COCH 3 ),1.60(s,3H,COCH 3 ), 1.52-1.71 (m, 8H, H-2", 7', 10'), 1.96 (br. d (broad doublet), 1H, H-4a'), 2.14 (br. s (broad singlet), 3H, H-4', 5b'), 2.61 (t, 2H, H-1"), 2.73 (br. s, 1H, H-2'), 3.39 (br. s, 1H, H-1'), 4.39, 4.49 (2s, 2H, H-9'), 5.13 (s, 1H, H-6'), 6.77 (s, 1H, H-5), 7.19 (s, 1H, COOH). 13 C-NMR (CDCl 3 ): δ=14.0(C-5”),20.7,20.9(4C,C-7’,10’,C Ac ),22.4(C-4”),28.6(C-3”),30.4(C-3’),30.7,31.7(C-1”,2”),33.7(C-4’),38.7(C-1’),45.5(C-2’),11 1.5(C-9'),123.9(C-5),128.0(C-5'),133.4(C-1),142.0(C-3),147.3(C-4),148.5(C-8'),151.4(C-2).

[0240] Example 1b: Purification of CBDA

[0241] A CBDA sample was prepared from the synthetic product of Example 1a, namely CBDA-diacetate obtained by ester hydrolysis and crystallization to obtain CBDA. After derivatization of CBDA with diazomethane, the sample was analyzed by GC-MS and contained 99.72% CBDA, with the only detectable impurity being 0.22% CBDVA.

[0242] Example 2: Isolation of CBDA-diacetate by carboxylation of CBD

[0243]

[0244] CBD (3.14 g, 10.0 mmol, purchased from Alb Hemp, USA) was dissolved in DMF (10 mL), and a DMF solution of methyl magnesium carbonate (2 M, 12.5 mL, 25.0 mmol) was added. The mixture was stirred at 130°C for 4 hours according to the method described by R. Mechoulam, Z. Ben-Zvi, Chem. Commun, 1969, 343-344. Water (5 mL) was added, and stirring was continued at room temperature for 1 hour, poured into water (100 mL), and extracted with ether (3 x 50 mL). The combined ether extracts were washed with Na 2 SO 4 Drying, filtration and concentration gave a mixture of CBD and CBDA containing about 75% CBDA. The crude CBD / CBDA mixture was treated with acetic anhydride as described in Example 1 to give CBDA-diacetate (3.05 g, 69%).

[0245] Example 3: Methylation of CBDA-diacetate (new compound)

[0246]

[0247] CBDA-diacetate (10 g, 22.6 mmol) was dissolved in acetonitrile (50 mL) and triethylamine (2.52 g or 3.46 mL, 24.9 mmol, 1,1 molar equivalent) was added with stirring at room temperature. Dimethyl sulfate (3.14 g or 2.4 mL, 24.9 mmol, 1.1 molar equivalent) was added dropwise to the stirred mixed solution at a rate that the mixture temperature did not exceed 50 °C and stirred at room temperature until TLC (RP-18 silica gel, MeOH / acetic acid: 19 / 1) showed complete conversion of the starting material (16 h). Alternatively, the mixed solution was stirred at 60 °C for 2 hours, poured into ice-cold 1 M aqueous HCl (250 mL), and the resulting suspension was extracted with dichloromethane (2 x 50 mL). The combined organic extracts were successively treated with 1 M aqueous HCl (1 x 100 mL), saturated NaHCO 3 The mixture was washed with aqueous solution (2x100 mL) and brine (1x100 mL). 2 SO 4 Dry, filter and concentrate to give CBDA-diacetate-methyl-ester (9.8 g, 95%) as a slightly yellow oil.

[0248] The compound was confirmed by high resolution mass spectrometry (HRMS): theoretical value C 27 H 36 O 6 [M+Na] + m / z=479.24041; Result: m / z=479.24105.

[0249] The measured optical rotation is =-67°(c=1.6g / 100mL, CHCl 3 ).

[0250] 1 H-NMR spectral data and 13 C-NMR spectrum data are as follows:

[0251] 1 H-NMR (CDCl 3 ): δ=0.91(t,3H,J=6.5Hz,H-5”),1.33(br.s.,4H,H-3”,4”),1.61(s,3H,COCH 3 ),1.70(s,3H,COCH 3 ),1.56-1.84(m,2H,H-2”),2.02-2.23(m,11H,H-1',3',4',7',10'),2.61(br. s,1H,H-2'),2.70(t,2H,J=3.9Hz,H-1”),3.47(br.s,1H,H-1’),3.87(s,3H,OCH 3 ),4.48,4.58(2s,2H,H-9'),5.23(s,1H,H-6'),6.84(s,1H,H-5).

[0252] 13 C-NMR (CDCl 3 ): δ=14.0(C-5”),20.7,20.9(2C,CH 3Ac ),22.4(C-4"),23.4(C-7'),28.6(C-3"),30.5(2C,C-2",3'),31.7(C-1"),33.6(C-4'),38.7(C-10'),45.5(C-2'),52.2(OCH 3 ),111.5(C-9'),124.0(C-5'),133.2(C-1),141.0(C-3),147.3(C-5),148.0(C-4),150.8(2C,C-2,8'),167.1,168.7(C=O).

[0253] Example 4: Deacetylation of CBDA-diacetate methyl ester (new compound)

[0254]

[0255] CBDA-diacetate-methyl-ester (4.57 g, 10.0 mmol) was dissolved in methanol (20 mL), sodium methoxide (54 mg, 1.0 mmol) or 1 M ammonia methanol solution (2.0 mL, 2.0 mmol ammonia) was added, and stirred at room temperature for 24 hours. For the reaction solution with sodium methoxide, Amberlyst IR 120 ion exchange resin (H+ form) was added to neutralize, filtered and concentrated. For the reaction solution with ammonia methanol solution, it was directly concentrated to obtain monodeacetylated CBDA-2-acetate methyl ester (4.15 g, 100%).

[0256] The compound was confirmed by high resolution mass spectrometry (HRMS): theoretical value C 25 H 34 O 5 [M+Na] + m / z=437.23039; Result: m / z=437.23027.

[0257] The measured optical rotation is =-16.2°(c=0.7g / 100mL,CHCl 3 )

[0258] 1 H-NMR spectral data and 13 C-NMR spectrum data are as follows: 1 H-NMR (CDCl 3 ): δ=0.80(t,3H,J=6.5Hz,H-5”),1.23(br.s,4H,H-3”,4”),1.53(s,3H,COCH 3 ),1.44-1.70(m,2H,H-2"),1.99-2.21(m,11H,H-1',3';4',7',10'),2.40-2.66(m,2H,H-1",2'),2.70,3.47(br.s,1H,H-1'),3.75(s,3H,OCH 3 ),4.33,4.53(2s,2H,H-9'),5.47(s,1H,H-6'),6.17(s,1H,H-5),6.51(s,1H,OH).

[0259] 13 C-NMR (CDCl 3 ):δ=14.0(C-5”),20.7(CH 3Ac),22.5(C-4"),23.7(C-7'),27.7(C-3"),30.8(2C,C-2",3'),31.8(C-1"),33.8(C-4'),38.1(C-10'),45.6(C-2'),52.0(OCH 3 ),112.0(C-9'),122.6(C-5'),135.2(C-1),141.7(C-3),142.6(C-5),146.5(C-4),155.9,157.1(C-2,8'),167.1,167.4(C=O).

[0260] Example 5a: Cyclization of CBDA-methyl acetate to Δ 9 -THCA-acetate methyl ester (new compound)

[0261]

[0262] Under nitrogen protection, a solution of CBDA-2-acetate methyl ester (2.07 g, 5.0 mmol), tetraethylene glycol dimethyl ether (0.24 mL), diisopropylethylamine (0.24 mg) and boron trifluoride diethyl ether (0.40 mL) in dichloromethane (50 mL) was stirred until TLC showed that the starting material was completely consumed (24 h). The reaction solution was successively treated with saturated NaHCO 3 solution, 2N HCl solution, saturated NaCl solution, Na 2 SO 4 The filtrate was concentrated and the residue was recrystallized from n-hexane to obtain Δ 9 -THCA-acetate methyl ester (2.0 g, 97%).

[0263] The compound was confirmed by high resolution mass spectrometry (HRMS): theoretical value C 25 H 34 O 5 [M+Na] + m / z = 437.22984; Result: m / z = 437.22970

[0264] The measured optical rotation is =-185°(c=0.9g / 100mL,CHCl 3 ).

[0265] 1 H-NMR spectral data and 13 C-NMR spectrum data are as follows:

[0266] 1 H-NMR (CDCl 3): δ=0.80(t,3H,J=7.0Hz,H-5″),1.19-1.42(m,4H,H-3″,4″),1.43-1.53(m,2H,H-2″),1.53(s, 3H,H-9'),1.62-1.74(m,4H,H-6',10'),1.70(s,3H,H-7'),2.02(br.s,2H,H-4'),2.14(s,3H,CH 3 C=O),2.41-2.49(m,4H,H-1”,5'),2.62(br.s,1H,H-1'),3.74(s,3H,OCH 3 ),6.21(s,1H,H-5),6.53(s,1H,H-2').

[0267] 13 C-NMR (CDCl 3 ): δ = 14.0 (C-5”), 19.4 (C-9’), 20.7 (CH 3Ac ),22.5(C-4”),23.7(C-10’),27.7(C-5’),30.1(C-4’),30.8(C-3”),31.8(C-2”),33.8(C-1”),38.1(C-1’),45.6(C-6’),52.0(OCH 3 ),77.4(C-8'),116.0(C-5),117.9(C-1),120.5(C-3),122.7(C-2'),141 .0(C-3'),142.6(C-2),146.4(C-4),157.1(C-6),167.4(COO),169.1(C=O Ac ).

[0268] Example 5b: Cyclization of CBDA-methyl acetate to Δ 8 -THCA-acetate-methyl ester (new compound)

[0269]

[0270] CBDA-acetate methyl ester (2.07 g, 5.0 mmol) was dissolved in toluene (10 mL), toluene-4-sulfonic acid monohydrate (10 mg, 0.05 mmol) was added, and the solution was heated to 80 ° C and stirred for 3 h. The solution was then cooled to room temperature and washed with saturated sodium bicarbonate solution. The organic phase was separated and anhydrous Na 2 SO 4 Dry, filter, and evaporate to dryness to obtain Δ 8 -THCA methyl ester (1.98 g, 96%).

[0271] Example 5c: Cyclization of CBD to Δ 9 -THC

[0272]

[0273] Under nitrogen atmosphere and room temperature, dry dichloromethane (60mL) solution of pure CBD (10g, 32mmol) was added to tetraethylene glycol dimethyl ether (0.48mL), diisopropylethylamine (0.48mL) and boron trifluoride diethyl ether complex (0.8mL, 6.5mmol) in dry dichloromethane (100mL) solution of vigorous stirring within 1 hour. Another portion of tetraethylene glycol dimethyl ether (0.24mL), diisopropylethylamine (0.24mg) and boron trifluoride diethyl ether complex (0.4mL, 3.3mmol) were added immediately afterwards, and the mixture was continued to be stirred for 3 hours under nitrogen atmosphere until thin layer chromatography (TLC) (RP-C18, methanol / acetic acid 19 / 1v / v) showed that the raw material was completely converted. The reaction mixture was first heated to saturated NaHCO 3 The sample was washed with 5% aqueous HCl (1 x 80 mL), then with 5% aqueous HCl (1 x 80 mL), and finally with saturated NaCl solution (3 x 200 mL) three times. Repeated washing with saturated sodium chloride solution was necessary to completely remove the reagent combination of tetraethylene glycol dimethyl ether and diisopropylethylamine. 2 SO 4 The organic phase was dried, filtered and concentrated in vacuo to give a clear yellowish oil. 9 -Tetrahydrocannabinol (9.89 g, 99% yield).

[0274] Compound confirmed by HRMS: theoretical value C 21 H 30 O 2 [M+Na] + m / z=314.2246; Result: m / z=314.2247.

[0275] The measured optical rotation is =-151°(c=1.0g / 100mL,CHCl 3 ).

[0276] Compound purity confirmed by GC-MS: Δ 9 -THC content>99%; no Δ detected 8 -iso-THC and Δ 8 -THC.

[0277] Example 5d: Cyclization of CBD to Δ using SiOx-BA 8 -THC

[0278]

[0279] Reagent SiOx-BA

[0280] A 35 mL DCM solution of boron trifluoride diethyl ether complex (4 mL, 3.48 g, 24.5 mmol) was added to oven-dried silica gel (10 g), and the mixture was vacuum dried in a rotary evaporator until the silica gel became active and appeared liquid. Next, the silica gel was mixed with a solution of p-toluenesulfonic acid monohydrate (8.0 g, 42 mmol) in ethanol (16 mL). The mixture was vacuum dried again in a rotary evaporator with the bath temperature set at 60°C to obtain the reagent "SiOx-BA".

[0281] Δ 8 -THC

[0282] A solution of CBD (10.0 g, 31.8 mmol) in dichloromethane (40 mL) was shaken with SiOx-BA (10 g) at room temperature until TLC (RP C 18 , MeOH / AcOH 19 / 1 v / v) indicated complete conversion of the starting material. Filtration, NaHCO 3 Solution washing filtrate, Na 2 SO 4 Dry and filter. Concentrate the filtrate to obtain Δ 8 -Tetrahydrocannabinol (9.8 g, 98% yield).

[0283] analyze

[0284] Measuring optical rotation =-283°(c=1.0g / 100mL, CHCl 3 This value is consistent with that reported in the literature (Marzullo, P.; Foschi, F.; Coppini, DA; Fanchini, F.; Magnani, L.; Rusconi, S.; Luzzani, M.; Passarella, D., J. Nat. Prod. 83202894-2901).

[0285] The NMR data are consistent with those reported in the literature (Marzullo, P.; Foschi, F.; Coppini, DA; Fanchini, F.; Magnani, L.; Rusconi, S.; Luzzani, M.; Passarella, D., J. Nat. Prod. 83202894-2901).

[0286] The compound was further confirmed by electron ionization mass spectrometry (EI-MS): m / z = 314 [M] + , 299[M-CH 3 ] + , 271[MC 3 H 7 ] + , 258[MC 4 H 8 ] + , 246[MC 5 H 8 ] + (Use Δ 8 -THC reverse Diels-Alder reaction characteristics), 231[MC 6 H 11 ] + .

[0287] Example 6: Conversion of THCA-acetate methyl ester to THCA-carbonate (new compound)

[0288]

[0289] THC-acetate methyl ester (1.0 g, 2.4 mmol) was stirred in 1M LiOH in methanol (20 mL) for 24 h. The resulting solution was poured into 2M HCl solution (100 mL) and extracted with dichloromethane (2 x 50 mL). The combined extracts were washed with saturated aqueous NaCl solution, Na 2 SO 4 Dry, filter and concentrate to obtain crude THCA. Dissolve crude THCA in toluene (20 mL), add trimethylamine (0.4 g, 4.0 mmol) and 2M phosgene in toluene (2 mL, 4 mmol). Stir at room temperature until all THC is consumed. Saturated NaHCO 3 Aqueous solution washing, Na 2 SO 4 Drying, filtration and concentration gave THCA carbonate (0.77 g, 83%).

[0290] The compound was confirmed by high resolution mass spectrometry (HRMS): theoretical value C 23 H 28 O 5 [M+Na] + m / z=407.18344; Result: m / z=407.18350.

[0291] The measured optical rotation is =-50.1°(c=1g / 100mL; in CHCl 3 ).

[0292] Record 1 H-NMR spectroscopy and 13 C-NMR spectrum, extract spectral data. Obtain significant NMR signals. The obtained THCA carbonate was dissolved in CDCl 3 It showed incomplete dissolution in d6-DMSO and decomposition in d6-DMSO.

[0293] 1 H-NMR (CDCl 3 )significant peaks: δ=0.91(t,3H,J=7.0Hz,H-5"),1.20-1.45(m,4H,H-3",4"),1.55(s,3H,H-9'),1.65(s,3H,H-7'),5.37(s,1H,H-2').

[0294] 13 C-NMR (CDCl 3 )significant signals: δ=14.1(C-5”),22.3(C-7’),25.1(C-9’),124.0(C-2’),135.4(C-3’),146.5,149.4(C=O).

[0295] Example 7: Synthesis of CBDA from CBD

[0296] 100 mmol CBD (31.5 g) was dissolved in 100 mL acetonitrile, and 300 mmol DBU (1,8-diazabicyclo[5.4.0]undec-7-ene) (45.6 g) was added. Carbon dioxide was then passed through the solution to form bubbles in the solution, producing CBDA with a purity and yield exceeding 99%. Post-treatment included washing with a 5 wt % aqueous solution of hydrogen chloride, washing with brine, extraction with an organic solvent, drying the extract with anhydrous sodium sulfate, and evaporating the solvent to produce CBDA with a purity greater than 99%. After derivatization of CBDA with diazomethane, the purity of the sample was confirmed by GC-MS.

[0297] pass 1 H-NMR (CDCl 3 )NMR and 13 C-NMR (CDCl 3 ) verified that the CBDA was consistent with the data published by Formato et al. (Molecules 2520202638; Figure 6).

[0298] Compounds and abbreviations

[0299] CBD: Cannabidiol; 2-[(1R, 6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol.

[0300] CBDA: Cannabidiolic acid; 2,4-dihydroxy-3-[(1R,6R)-3-methyl-6-propyl-1-en-2-ylcyclohex-2-en-1-yl]-6-pentylbenzoic acid.

[0301] THC: Δ 9 -Tetrahydrocannabinol (delta-9Tetrahydrocannabinol); (6aR, 10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol.

[0302] THC: Δ 9 -Tetrahydrocannabinolic acid (delta(9)-Tetrahydrocannabinolic acid); (6aR, 10aR)-1-hydroxy-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid.

[0303] THCV: Tetrahydrocannabivarin; (6aR, 10aR)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol.

[0304] THCVA: Tetrahydrocannabivarinic acid; (6aR, 10aR)-1-hydroxy-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid.

[0305] THCP: Tetrahydrocannabiphorol; (6aR, 10aR)-6,6,9-trimethyl-3-heptyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol.

[0306] THCPA: delta(9)-Tetrahydrocannabiphorolic acid; (6aR, 10aR)-1-hydroxy-6,6,9-trimethyl-3-heptyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid.

Claims

1. Compounds shown in Formula I in, R 1 is methyl-4-(prop-1-en-2-yl)-cyclohex-1-en-3-yl (limonenyl); R 2 is acetate, propionate, butyrate or OH; R 3 is propyl, pentyl or heptyl; R 4 is methyl, ethyl or propyl; R 5 is methyl, ethyl or propyl, or Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl or methyl-4-(-2-propyl)-cyclohex-5-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, and R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 is methyl, ethyl or propyl, and R 5 is methyl, ethyl or propyl, or Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, where R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 and R 5 Does not exist, that is, R 4 and R 5 connected to a single bond and forming a ring structure.

2. The compound according to formula I of claim 1 in, R 1 is methyl-4-(prop-1-en-2-yl)-cyclohex-1-en-3-yl (limonenyl); R 2 is acetate or OH; R 3 is propyl, pentyl or heptyl; R 4 is methyl; R 5 Methyl, or Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl or methyl-4-(-2-propyl)-cyclohex-5-en-3-yl, wherein R 2 is O, and R 1 and R 2 Together they form a ring structure, and R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 is methyl, and R 5 Methyl, or Among them, R 1 is methyl-4-(2-propyl)-cyclohex-1-en-3-yl, R 2 is O, and R 1 and R 2 Together they form a ring structure, where R 2 is an inner ring atom, R 3 is propyl, pentyl or heptyl, R 4 and R 5 Does not exist, that is, R 4 and R 5 connected to a single bond and forming a ring structure.

3. The compound according to claim 1 or 2, selected from:

4. A method for synthesizing and / or purifying tetrahydrocannabinolic acid (THCA) alkanoates and / or cannabidiol (CBDA) dialkanoates, preferably tetrahydrocannabinolic acid acetate and / or cannabidiol diacetate, comprising the following steps: - Providing a crude plant extract containing a mixture of cannabinoid acids, or providing CBDA; - contacting and / or reacting the crude plant extract or CBDA with an acylating agent, preferably an acetylating agent, and a chemical base to obtain THCA alkanoate and / or CBDA dialkanoate, preferably THCA acetate and / or CBDA diacetate; and - separating the THCA alkanoates and / or CBDA dialkanoates obtained, preferably THCA acetate and / or CBDA diacetate, Wherein, the acylating agent is selected from C1-C 10 an aliphatic or aromatic anhydride, preferably acetic anhydride, Wherein, the chemical base is preferably a tertiary amine, such as pyridine or preferably triethylamine, Among them, separation is carried out by crystallization.

5. The method according to claim 4, characterized in that Crystallization is carried out in n-pentane or n-hexane.

6. The method according to claim 4 or 5, characterized in that The crude plant extract is extracted by enzymatic method.

7. The method according to any one of claims 4 to 6, characterized in that The step further comprises: treating the obtained CBDA diacetate with an alkylating agent to obtain a first CBDA diacetate derivative, preferably CBDA-diacetate methyl ester of formula II, wherein the alkylating agent can be, for example, C1-C 10 dialkyl sulfate, preferably dimethyl sulfate, 8. The method according to claim 7, characterized in that The method further comprises the steps of: removing the acyl group of the first CBDA diacetate derivative to obtain a CBDA monoacetate derivative, preferably CBDA-2-acetate methyl ester of formula III.

9. The method according to claim 8, characterized in that The method further comprises the step of converting the CBDA monoacetate derivative into a THCA monoacetate derivative, preferably THCA 2-acetate methyl ester of formula IVa.

10. The method according to claim 9, characterized in that The method comprises the steps of converting the THCA 2-acetate methyl ester into a THCA carbonate of formula V, preferably via a THCA intermediate.

11. The method according to any one of claims 7 to 10, characterized in that The purity of the derivative obtained is at least 70%, preferably 90%, more preferably 99%.

12. The method according to any one of claims 4 to 11, characterized in that There is no distillation step and / or there is no chromatography step.

13. The method according to any one of claims 4 to 12, characterized in that The crude plant extract is obtained from a plant of the Cannabaceae family, which is preferably selected from the group consisting of common cannabis, Indian cannabis and wild cannabis.

14. The compound for use in medicine according to any one of claims 1 to 3.

15. The compound according to claim 14, for treating or preventing diseases related to cannabinoid receptors, wherein the cannabinoid receptors are one or more of CB1, CB2, 5HT1A, 5HT2A, GPR18, GPR55, GPR19, TRPV1, TPRV2, PPARy or μ-opioid receptors.

16. A compound according to claim 14 for use in treating a condition associated with or benefiting from COX-2 inhibition, wherein the compound is preferably CBDA-2-acetate.

17. The method according to any one of claims 4 to 13, characterized in that The contacting and / or reacting of the crude plant extract with the acylating agent and the chemical base comprises: dissolving the crude plant extract in a suitable solvent under shaking at room temperature, adding the acylating agent dropwise under stirring while keeping the solvent temperature below 50° C., and further contacting and / or reacting at room temperature for 1 to 4 hours.

18. Convert CBD to Δ 9 -THC method, comprising the steps of: - preparing a first solution comprising CBD in an organic solvent; - preparing a second solution comprising tetraethylene glycol dimethyl ether, diisopropylethylamine and boron trifluoride diethyl ether complex dissolved in an organic solvent; - adding the first solution to the second solution to obtain a reaction mixture; - optionally adding a further portion of the second solution to the reaction mixture; and - Get Δ 9 -THC, Wherein, the CBD is converted into Δ 9 -THC is carried out at a temperature of 10°C to 40°C, preferably 20°C to 30°C, the conversion of CBD into Δ 9 -THC was carried out under a protective gas atmosphere.

19. A method for synthesizing cannabidiol acid (CBDA), comprising the steps of: - preparing a solution comprising CBD in an organic solvent; - adding a non-nucleophilic base to the solution, wherein the non-nucleophilic base is preferably DBU (1,8-diazabicyclo[5.4.0]undec-7-ene); and - introducing carbon dioxide into the solution, preferably by bubbling carbon dioxide into the solution, to obtain CBDA.

20. The method according to claim 19, further comprising the steps of: - washing the solution with a neutralizing solution, for example aqueous hydrogen chloride solution; - optionally, repeatedly washing the solution with NaCl solution; and - extracting the solution with a second organic solvent to obtain an extract, optionally drying the extract, and evaporating the second organic solvent from the extract to obtain CBDA, preferably in crystalline form.